However, a randomized phase II study showed that higher levels of IGF-I, IGF-II and IGFBP-3 or lower levels of IGFBP-2 were associated with improved overall survival in metastatic PaC patients treated with ganitumab versus placebo [54]. This evidence concerns the gene IGFBP2 and gonorrhea.